Abstract: Objective To analyze survival status of liver cancer inpatients in a cancer hospital in Guangxi from 2010 to 2020. Methods Based on the hospital registration system, an active⁃passive follow⁃up was performed for liver cancer inpatients in a cancer hospital in Guangxi from January 2010 to December 2020, with follow⁃up ending on August 6, 2024. Kaplan⁃Meier survival analysis was used to calculate survival rates. Wilcoxon rank⁃sum was used to analyze survival differences by age, sex, Barcelona Clinical Liver Cancer (BCLC), and treatment periods. Results A total of 12, 177 liver cancer patients were included, with an average age of （60.03±11.79） years, and a higher proportion of males than females (86.19% vs 13.81%). The median overall survival was 14.53 months, with 1⁃, 3⁃, 5⁃, and 10⁃year survival rates of 52.25%, 34.20%, 28.11%, and 19.89%, respectively, the survival rate of male patients was lower than that of female patients at all timepoints (P<0.001). The survival curves differed statistically significant among age groups, with lower 5⁃year survival rates in the <40 (26.55%) and ≥80 (19.21%) age groups compared with the 40-79 age group (27.97%-28.48%). The 5⁃year survival rates of patients in BCLC stages A, B, C, and D were 69.56%, 42.95%, 15.72%, and 6.20%, respectively (P<0.001). The 1⁃, 3⁃, and 5⁃year survival rates for patients from 2010 to 2015 were 50.49%, 32.49%, and 26.41%, respectively, which improved to 53.72%, 35.60%, and 29.45% during 2016—2020, with statistically significant differences (P<0.001). Conclusions The long⁃term survival rates of liver cancer inpatients in Guangxi from 2016 to 2020 showed a significant upward trend, but remained at a relatively low level. Patients with young/old age, male, and advanced BCLC stages still face challenges in survival rates, and should be prioritized  focus. Comprehensive prevention and control measures for liver cancer should be further strengthened.

Key words: Liver Cancer, Cancer registry, Hospital registry, Follow?up, Survival rate